# Phase I/Ib Study of GWN323 Alone and in Combination With PDR001 in Patients With Advanced Malignancies and Lymphomas

> **NCT02740270** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 92 (actual)

## Conditions studied

- Solid Tumors
- Lymphomas

## Interventions

- **DRUG:** GWN323
- **DRUG:** PDR001

## Key facts

- **NCT ID:** NCT02740270
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07-22
- **Primary completion:** 2020-03-03
- **Final completion:** 2020-03-03
- **Target enrollment:** 92 (ACTUAL)
- **Last updated:** 2021-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02740270

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02740270, "Phase I/Ib Study of GWN323 Alone and in Combination With PDR001 in Patients With Advanced Malignancies and Lymphomas". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02740270. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*